Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The claims align with the provided FDA label content: ZELSUVMI is indicated for topical treatment of molluscum contagiosum (MC), and the statements about missing efficacy/safety detail are consistent with the absence of those specific details in the provided information.
Category Scores
Accurate Statements
Treat molluscum contagiosum (MC) with ZELSUVMI (berdazimer) topical gel.
Supported by Section 1 (INDICATIONS AND USAGE) and consistent with Section 2 (DOSAGE AND ADMINISTRATION) and Section 14 (CLINICAL STUDIES) where MC lesions are treated.
The provided information does not include specific efficacy results for Zelsuvmi (e.g., response rates, lesion count changes, or median time-to-event).
Consistent with the provided label excerpt emphasizing endpoints (e.g., complete clearance at Week 12/Week 8) without listing the specific examples referenced (response rates, lesion count changes, median time-to-event).
The provided information does not include a detailed safety profile for Zelsuvmi (e.g., common adverse reactions, severity, or rates of discontinuation).
Consistent with the provided excerpt: it mentions adverse reactions ≥1% and more frequently than vehicle and application-site reactions, but does not provide a detailed safety profile with severity/discontinuation rates in the supplied text.
Unsupported Statements
Contradictions
Important Omissions
No duration/specific dosing details were stated in the treatment/indication claim (e.g., once daily up to 12 weeks).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are limited to indication and to assertions about absence of certain efficacy/safety details in the provided information; they do not introduce dosing errors or contradict labeled safety requirements.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement